You’ve read about the top 10 molecules with publications from August, but what about the ones we found interesting that didn’t make it into Molecules of the Month? There were five runners-up from August 2022, including:
- a highly selective, dihydropyrimidinone-based CSF1R switch-control kinase inhibitor
- a non-competitive, allosteric CXCR1/2 inhibitor with inflammation-independent antinociceptive effects
- a drug for glioblastoma repurposed as a pan-apicomplexan antiparasitic agent
You can read more about all five molecules in this article, including details about their mechanism of action, their molecular target, indications, and more below.
request a trial
Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.
Interested in learning more? Submit this form to request a trial.
